Our study was the first to explore the possible mechanism of the neuroprotective effects of loganin as a potential candidate drug for AD that could ameliorate Aβ deposition, improve tau pathology and prevent cognitive impairment in 3xTg-AD mice at the level of hippocampal proteomics. The gene discussed is MAPT; the disease is Alzheimer disease.